Innovent Announces 2024 Annual Results and Business Updates
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops,...
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...